Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A STUDY INVESTIGATES NEW CARE MODEL OF SHORTER HOSPITAL STAY FOLLOWED BY AT-HOME TREATMENT WITH SC2WEAR SUBCUTANEOUS FUROSEMIDE

Trial Profile

A STUDY INVESTIGATES NEW CARE MODEL OF SHORTER HOSPITAL STAY FOLLOWED BY AT-HOME TREATMENT WITH SC2WEAR SUBCUTANEOUS FUROSEMIDE

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Furosemide (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms SUBQ-HF
  • Most Recent Events

    • 18 Jul 2017 New trial record
    • 24 Jan 2017 According to a scPharmaceuticals media release, Five centers are participating in the pilot phase including Emory University Hospital, Massachusetts General Hospital, Mayo Clinic, Duke University Medical Center and Metro Health System. The main study is expected to include up to an additional 20 centers in the US and the Michael Felker, MD, Duke University is the principal investigator.
    • 24 Jan 2017 According to a scPharmaceuticals media release, Enrollment for the pilot phase started in January of 2017 and the anticipated read out of the SUBQ-HF study program is in 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top